JP2012211164A5 - - Google Patents

Download PDF

Info

Publication number
JP2012211164A5
JP2012211164A5 JP2012138485A JP2012138485A JP2012211164A5 JP 2012211164 A5 JP2012211164 A5 JP 2012211164A5 JP 2012138485 A JP2012138485 A JP 2012138485A JP 2012138485 A JP2012138485 A JP 2012138485A JP 2012211164 A5 JP2012211164 A5 JP 2012211164A5
Authority
JP
Japan
Prior art keywords
val xaa
xaa pro
xau
isomer
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012138485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012211164A (ja
Filing date
Publication date
Priority claimed from US08/896,394 external-priority patent/US6143721A/en
Application filed filed Critical
Publication of JP2012211164A publication Critical patent/JP2012211164A/ja
Publication of JP2012211164A5 publication Critical patent/JP2012211164A5/ja
Pending legal-status Critical Current

Links

JP2012138485A 1997-07-18 2012-06-20 ドラスタチン15誘導体 Pending JP2012211164A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/896,394 1997-07-18
US08/896,394 US6143721A (en) 1997-07-18 1997-07-18 Dolastatin 15 derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008315263A Division JP5122429B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体

Publications (2)

Publication Number Publication Date
JP2012211164A JP2012211164A (ja) 2012-11-01
JP2012211164A5 true JP2012211164A5 (enExample) 2013-01-10

Family

ID=25406130

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2000503101A Expired - Fee Related JP4508413B2 (ja) 1997-07-18 1998-07-07 ドラスタチン15誘導体
JP2008315263A Expired - Fee Related JP5122429B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体
JP2008315269A Expired - Fee Related JP5047935B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体
JP2012138485A Pending JP2012211164A (ja) 1997-07-18 2012-06-20 ドラスタチン15誘導体

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2000503101A Expired - Fee Related JP4508413B2 (ja) 1997-07-18 1998-07-07 ドラスタチン15誘導体
JP2008315263A Expired - Fee Related JP5122429B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体
JP2008315269A Expired - Fee Related JP5047935B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体

Country Status (32)

Country Link
US (6) US6143721A (enExample)
EP (1) EP0991658B1 (enExample)
JP (4) JP4508413B2 (enExample)
KR (1) KR100579748B1 (enExample)
CN (1) CN1268636C (enExample)
AR (1) AR018501A1 (enExample)
AT (1) ATE314387T1 (enExample)
AU (1) AU750120B2 (enExample)
BG (1) BG65212B1 (enExample)
BR (1) BR9810911A (enExample)
CA (1) CA2296036C (enExample)
CO (1) CO4990967A1 (enExample)
CY (1) CY1107047T1 (enExample)
CZ (1) CZ303045B6 (enExample)
DE (1) DE69832982T2 (enExample)
DK (1) DK0991658T3 (enExample)
ES (1) ES2258819T3 (enExample)
HR (1) HRP980397A2 (enExample)
HU (1) HU228996B1 (enExample)
ID (1) ID24669A (enExample)
IL (1) IL133784A (enExample)
MY (1) MY135057A (enExample)
NO (1) NO326827B1 (enExample)
NZ (1) NZ502296A (enExample)
PL (1) PL197884B1 (enExample)
PT (1) PT991658E (enExample)
RU (1) RU2195462C2 (enExample)
SK (1) SK286581B6 (enExample)
TR (2) TR200103545T2 (enExample)
TW (1) TW533217B (enExample)
WO (1) WO1999003879A1 (enExample)
ZA (1) ZA986358B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6686336B2 (en) 2000-02-08 2004-02-03 Federal Government As Represented By The Department Of Veterans Affaires N-terminal D(-)-penicillamine peptides as aldehyde sequestration agents
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
RU2342399C2 (ru) * 2002-03-22 2008-12-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные гемиастерлина и их применение при лечении рака
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
DK1545613T3 (da) * 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
PL2489364T3 (pl) 2003-11-06 2015-06-30 Seattle Genetics Inc Związki monometylowaliny zdolne do sprzęgania do przeciwciał
WO2006063135A2 (en) * 2004-12-09 2006-06-15 Eisai R & D Management Co., Ltd. Tubulin isotype screnning in cancer therapy using hemiasterlin analogs
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
PE20140625A1 (es) 2007-07-16 2014-05-29 Genentech Inc ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
PL2176296T3 (pl) 2007-07-16 2012-07-31 Genentech Inc Przeciwciała anty-CD79B i immunokoniugaty i sposoby stosowania
DE102007039706A1 (de) 2007-08-22 2009-02-26 Erhard Prof. Dr.-Ing. Kohn Chemischer Sensor auf Diamantschichten
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
BR112012014899A2 (pt) 2009-12-18 2017-03-14 Idenix Pharmaceuticals Inc composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus
RU2573994C2 (ru) 2010-02-10 2016-01-27 Иммьюноджен, Инк Антитела против cd20 и их применение
KR20120140658A (ko) 2010-02-12 2012-12-31 파마사이언스 인크. Iap bir 도메인 결합 화합물
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
CN114262344A (zh) 2014-02-28 2022-04-01 杭州多禧生物科技有限公司 带电荷链接体及其在共轭反应上的应用
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
CA2989269C (en) 2015-06-15 2020-09-22 Robert Yongxin Zhao Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule
CN108449940B (zh) 2015-07-12 2021-06-08 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CN116143678A (zh) 2016-11-14 2023-05-23 杭州多禧生物科技有限公司 偶联连接体,含有此连接体的细胞结合分子-药物偶联物及其制备和应用
MX2024002571A (es) 2021-09-03 2024-03-20 Toray Industries Composicion farmaceutica para tratamiento y/o prevencion de cancer.
KR20240095442A (ko) 2021-11-03 2024-06-25 항저우 디에이씨 바이오테크 씨오, 엘티디 항체의 특이적 접합

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
SG87056A1 (en) * 1991-08-09 2002-03-19 Teikoku Hormone Mfg Co Ltd Novel tetrapeptide derivative
US5533097A (en) * 1992-02-26 1996-07-02 Motorola, Inc. Portable communication system comprising a local and wide area communication units which can store a communication when the wide area communication system is not available
US5448045A (en) * 1992-02-26 1995-09-05 Clark; Paul C. System for protecting computers via intelligent tokens or smart cards
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
HUT71398A (en) * 1992-05-20 1995-11-28 Basf Ag Derivatives of dolastatin
NZ258882A (en) * 1992-12-16 1997-06-24 Basf Ag Antineoplastic peptides and compositions thereof
US5554993A (en) * 1994-01-04 1996-09-10 Panasonic Technologies, Inc. Global position determining system and method
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5554725A (en) * 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5618232A (en) * 1995-03-23 1997-04-08 Martin; John R. Dual mode gaming device methods and systems
US5970143A (en) * 1995-11-22 1999-10-19 Walker Asset Management Lp Remote-auditing of computer generated outcomes, authenticated billing and access control, and software metering system using cryptographic and other protocols
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
CA2287379C (en) * 1997-01-10 2005-10-04 Silicon Gaming-Nevada Method and apparatus for providing authenticated, secure on-line communication between remote locations
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6554705B1 (en) * 1997-08-22 2003-04-29 Blake Cumbers Passive biometric customer identification and tracking system
US6629591B1 (en) * 2001-01-12 2003-10-07 Igt Smart token
US6438382B1 (en) * 2001-02-14 2002-08-20 Telefonaktiebolaget Lm Ericsson (Publ.) Expedited location determination in analog service areas

Similar Documents

Publication Publication Date Title
JP2012211164A5 (enExample)
JP2016538254A5 (enExample)
JP2011121989A5 (enExample)
JP2007269812A5 (enExample)
JP2010534684A5 (enExample)
ES2603058T3 (es) Láminas, esponjas y bayetas revestidas de un tratamiento antimicrobiano
JP2013518057A5 (enExample)
JP2013542247A5 (enExample)
MX2019013263A (es) Inhibidores de la recirculacion de acidos biliares para el tratamiento de enfermedades hepaticas colestasicas pediatricas.
JP2009225798A5 (enExample)
JP2012512907A5 (enExample)
JP2012530060A5 (enExample)
NZ593524A (en) A nonapeptide with anti-tumour activity
JP2015024998A5 (enExample)
JP2015518055A5 (enExample)
JP2014515013A5 (enExample)
JP2009535462A5 (enExample)
JP2013534248A5 (enExample)
ES2634538T3 (es) Composición de detergente recubierta y proceso de fabricación
JP2013520405A5 (enExample)
EP2588099A4 (en) METHOD OF TREATING THE RESTLESS LEG SYNDROME
JP2011137005A5 (enExample)
CL2008003322A1 (es) Compuestos derivados de acidos de ciclobutanoamino, moduladores de receptores s1p; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de artritis, enfermedades autoinmunes, diabetes tipo i, enfermedad pulmonar obstructiva cronica, entre otras.
JP2013503110A5 (enExample)
BR112012017691A2 (pt) nova composição